Understand Deeper.
Predict Smarter.
Our unique AI platform seamlessly integrates morphology and genomics to accurately predict treatment response while delivering clear, visual insights into scientifically validated biological mechanisms.
Tailoring treatments to a patient’s unique genomic or biomarker profile.
Pinpointing those most likely to benefit with greater effectiveness and fewer side effects.
Encompassing cutting-edge targeted and immunotherapies.
We developed a one-of-a-kind phenotype atlas which learnt high-level information from diagnostic tissue images across all landscapes of cancer pathology with corresponding genomic variations, allowing us to quickly and efficiently apply to new use cases to predict outcome, treatment response, and gene mutations based on strong scientific and biologically interpretable evidence.
Here’s what sets us apart from genomic assays:
We deliver high-confidence predictions powered by advanced AI algorithms.
We enable molecular biomarker discovery by preserving tissue integrity for advanced multiomic and spatial proteogenomic analysis.
We provide affordable testing without compromising on quality or performance.
We provide answers with quick turnaround times than the clinically used genomic testing.
Cloud-based and decentralized for easy global implementation and scalable logistics.
With PATHOMIQ AI predictive tests, physicians are able to personalize treatment for each patient.
First In class H&E Interpretable platform:
Expanded analytics include cancer detection and grading as a part of the overall AI prediction that helps pathologists in accurate diagnosis.
Cellular and glandular quantifications for regions of interest in reference to treatment response.
Genomic expression mapping yields insight into the mechanistic basis of the predicted outcome.
The first-of-its-kind, our comprehensive phenotype atlas combines expert pathologist supervision with cutting edge AI-learned information. Trained using thousands of slides spanning multiple tissues from a diverse set of medical institutions, this powerful asset allows us to quickly deploy our platform to new and specific use-cases using only a minimal amount of outcome data.
Our platform outperforms clinical and genomic gold standards. We have shown to accurately predict risk of metastasis and response to anti-androgen therapy in prostate, as well as pathologic complete response in triple negative breast cancer.
Our platform can predict genotypes and molecular alterations directly from H&E-stained WSIs with high accuracy, enabling timely and optimal treatment decision-making for positive clinical outcomes.
Our platform identifies regions of interest that are predictive to specific therapy response, allowing for focused molecular analysis.
Our powerful method allows for precision, gland-level cancer grading to improve accuracy of pathologists.
Our first-in-kind comprehensive phenotype atlas combined multiple expert pathologists annotations with cutting-edge Al-learned previously unreported morphological features. It is trained using thousands of slides spanning multiple tissues from a diverse set of cancer centers of excellence. This powerful asset allows us to quickly deploy our platform to new and specific use-cases even with a small amount of outcome data.
Our platform outperforms clinical and genomic gold standards. We have shown it accurately predicts risk of metastasis and response to anti-androgen therapy against prostate cancer, pathologic complete response to approved neoadjuvent therapies of triple negative breast cancer, and stratification of patients for hormonal and chemo+ hormonal therapy of ER+/Her2- breast cancer patients better than the widely used SOC genomic test.
Our platform can predict genotypes and molecular alterations directly from H&E-stained WSIs with high accuracy, enabling timely and optimal treatment decision-making for positive clinical outcomes.
Our platform identifies regions of interest that are predictive of specific therapy response, allowing for focused molecular analysis.
Our powerful method allows for precision, gland-level cancer grading to improve accuracy of cancer diagnosis.
PATHOMIQ AI, headquartered in Silicon Valley, USA, was founded by a multidisciplinary team of outstanding biomarker discovery researchers, data scientists, and clinicians with 100+ man-years of experience in their areas of specialty.
CEO & Co-Founder
Chief Medical Officer
Head of Pathology &
Co-Founder
In an era where oncology is evolving at unprecedented rate, our resources keep you informed and inspired.
Stay ahead of the curve with insights that matter.
